Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.
Jaime Feliú-BatlleMónica Jorge FernándezTeresa MacarullaBartomeu MassutiAna AlberoJosé Federico González GonzálezGuillermo Quintero-AldanaJuan Ignacio Delgado-MingoranceAna Fernández MontesCarmen García PiernaviejaManuel Valladares-AyerbesAna María López MuñozRebeca Mondéjar SolísPilar VicenteEsther Casado GonzalezIrene González CebriánGuillermo López-VivancoPublished in: Cancer chemotherapy and pharmacology (2021)
Our study confirms the clinical benefit of the combination of nab-paclitaxel and gemcitabine in an elderly population with pancreatic cancer in terms of improved survival and clinical response. However, we were unable to confirm a benefit in terms of quality-of-life.